$0.97
-0.11 (-9.99%)
Open$1.08
Previous Close$1.08
Day High$1.11
Day Low$0.95
52W High$2.26
52W Low$0.69
Volume—
Avg Volume191.5K
Market Cap33.90M
P/E Ratio—
EPS$-1.74
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,814.2% upside
Current
$0.97
$0.97
Target
$38.05
$38.05
$26.78
$38.05 avg
$46.02
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.33M | 11.14M | 10.37M |
| Net Income | -3,474,981 | -2,537,744 | -2,319,778 |
| Profit Margin | -28.2% | -22.8% | -22.4% |
| EBITDA | -5,324,397 | -5,017,327 | -4,875,631 |
| Free Cash Flow | -1,460,004 | -1,340,766 | -1,751,994 |
| Rev Growth | +17.2% | +1.6% | +25.0% |
| Debt/Equity | 0.34 | 0.29 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |